SCHEMBL15051181

SCHEMBL15051181

CCC(O)[C@@H](O)c1cccc(I)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 7/20 0.50
CYP3A4 P08684 6/20 0.50
CYP2D6 P10635 6/20 0.50
SLC6A2 P23975 6/20 0.50
SLC6A4 P31645 6/20 0.50
KCNH2 Q12809 4/20 0.50
LMNA P02545 2/20 0.39
PPARG P37231 1/20 0.38
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
ADRB1 P08588 1/20 0.37
MIF P14174 1/20 0.37
HTR2A P28223 1/20 0.37
ADRA1A P35348 1/20 0.37
HTR2B P41595 1/20 0.37
AOC3 Q16853 1/20 0.35
TRPA1 O75762 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC8 Q9BY41 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15050281 1.00 SLC6A3 (0.50) SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL15051180 1.00 SLC6A3 (0.50) SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL15050279 1.00 SLC6A3 (0.50) SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL15050282 1.00 SLC6A3 (0.50) SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL15051117 0.83 SLC6A2 (0.46) SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL15051120 0.83 SLC6A2 (0.46) SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL15051279 0.83 SLC6A2 (0.46) SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL15051119 0.83 SLC6A2 (0.46) SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL15051280 0.83 SLC6A2 (0.46) SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL11605816 0.82 CYP2D6 (0.47) SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease BIO-PHARM SOLUTIONS CO., LTD. (KR) 2024-03-19 US disclosed
EP-4204395-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE Bio-Pharm Solutions Co., Ltd. (KR) 2023-07-05 EP disclosed
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
EP-2797881-B1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME BIO PHARM SOLUTIONS CO LTD (KR) 2018-11-14 EP disclosed
US-9504668-B2 Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-29 US disclosed
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-01-28 US disclosed
EP-2968211-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME Bio-Pharm Solutions Co., Ltd. (KR) 2016-01-20 EP disclosed
US-9029589-B2 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-05-12 US disclosed
EP-2797881-A1 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same Bio-Pharm Solutions Co., Ltd. (KR) 2014-11-05 EP disclosed
WO-2014142519-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2014-09-18 WO disclosed
WO-2013100566-A1 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-07-04 WO disclosed
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME MYLK, PDE3A, TNNC1 SLC6A3 1979/4885CYP3A4 58/4885CYP2D6 353/4885
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease SNCA, MAPT, CHAT SLC6A3 400/4885CYP3A4 4695/4885CYP2D6 4798/4885
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME SCN1A, GABARAPL1, NAA10 SLC6A3 2586/4885CYP3A4 860/4885CYP2D6 1222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.